

CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL

(Only for Continuation or Divisional applications under 37 CFR 1.53(d))

In re prior PATENT APPLICATION of
Inventor(s): BOUCHARD et al.

Group Art Unit: 1654

Examiner: Delacroix-Muirhead

Appln. No. 08 | 786,937
Series Code | Serial No.

Filed: January 22, 1997

Hon. Assistant Commissioner for Patents
Box CPA
Washington, DC 20231

Atty. Dkt. PM 235299

960018PH

Parent M#

Client Ref

Date: July 31, 2000

**DO NOT USE THIS FORM IF PARENT WAS A CPA
FILED ON/AFTER 5/29/00; USE RCE FORM PAT-252**

This is a request for a ☒ continuation or ☐ divisional application under 37 CFR 1.53(d), (continued prosecution application (CPA)) of the above prior application number, entitled

LHRH-Antagonists in the Treatment of Fertility Disorders

RECEIVED

AUG 03 2000

NOTES

TECH CENTER 1600/2900

FILING QUALIFICATIONS: The prior application identified above cannot be a CPA filed on/after 5/29/00 but must be a nonprovisional application filed before 5/29/00 that is either: (1) complete as defined by 37 CFR 1.51(b), or (2) the national stage of an international application in compliance with 35 U.S.C. 371, i.e., having a \$102(e) date granted and is neither abandoned nor its proceedings terminated and its issue fee has not been paid (unless item 6A below is X'd).

C-I-P NOT PERMITTED: A continuation-in-part application cannot be filed as a CPA under 37 CFR 1.53(d), but must be filed under 37 CFR 1.53(b).

EXPRESS ABANDONMENT OF PRIOR APPLICATION: The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 CFR 1.53(b) must be used to file a continuation, divisional, or continuation-in-part of an application that is not to be abandoned.

ACCESS TO PRIOR APPLICATION: The filing of this CPA will be construed to include a waiver of confidentiality by the applicant under 35 U.S.C. 122 to the extent that any member of the public who is entitled under the provisions of 37 CFR 1.14 to access to, copies of, or information concerning, the prior application may be given similar access to, copies of, or similar information concerning, the other application or applications in the file jacket.

35 U.S.C. 120 STATEMENT: In a CPA, no reference to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 U.S.C. 120 and to every application assigned the application number identified in such request, 37 CFR 1.78(a).

1. ☐ Enter the unentered amendment previously filed on _____ in the prior nonprovisional application. (Include claim fees on page 2).

2. ☒ A preliminary amendment is enclosed. (See page 3 for additional claims fees).

3. This application is filed by fewer than all the inventors named in the prior application, 37 CFR 1.53(d)(4).

a. ☐ DELETE the following inventor(s) named in the prior nonprovisional application:

| | | |
|----------|----------|--------|
| 1. _____ | 2. _____ | OP |
| 3. _____ | 4. _____ | OP |
| | | 690.00 |
| | | 18.00 |
| | | 870.00 |

b. ☐ The inventor(s) to be deleted are set forth on a separate sheet attached hereto.

4. ☐ A new power of attorney is enclosed.

5. Information Disclosure Statement is enclosed:

| | | |
|-------------------------------------|--|---|
| <input type="checkbox"/> IDS Letter | <input type="checkbox"/> Citing Appln. | <input type="checkbox"/> Foreign Search Report/OA |
| <input type="checkbox"/> PTO-1449 | | <input type="checkbox"/> Cited Documents |

6. ☐ **PRELIMINARY AMENDMENT** to be entered before fee calculation (Do not make amendments here except cancellation of whole claims or multiple dependencies for purpose of reducing the filing fee (on page 2) per MPEP § 506 and 607; do not cancel all claims.):

- 6A. ☐ The issue fee has been paid in the parent, but this CPA Request is based on a Rule 313(c)(3) petition and Rule 53(d)(1)(ii)(A).

7. ☐ Attached is a Rule 103(a) Petition to Suspend Action

FILING FEE

THE FOLLOWING FILING FEE IS BASED ON THE CLAIMS
EXISTING IN THE PRIOR APPLICATION AS AMENDED AT 1 & 6 ABOVE

| | <u>Large/Small Entity</u> | <u>Fee Code</u> |
|---|--|--|
| 8. <input type="checkbox"/> Small Entity Statement Filed <input type="checkbox"/> previously (still valid) <input type="checkbox"/> herewith | | |
| 9. Basic filing fee ----- | <input checked="" type="checkbox"/> Utility Appln. -- \$690/\$345 \$ 690 <input type="checkbox"/> Design Appln. -- \$310/\$155 \$ 0 <input type="checkbox"/> Plant Appln. -- \$480/\$240 \$ 0 <input type="checkbox"/> Reissue Appln. -- \$690/\$345 \$ 0 | (131/231) (132/232) (133/233) (134/234) |
| 10. (reserved) | | |
| 11. Total Effective Claims 20 minus 20 = * 0 x \$18/\$9 = + 0 (103/203) | | |
| 12. Independent Claim 2 minus 3 = * 0 x \$78/\$39 = + 0 (102/202) | | |
| *If answer is zero or less, enter "0" | | |
| 13. If <u>any proper</u> (ignore improper) multiple dependent claim is present, <input type="checkbox"/> add \$260/\$130 + 0 (104/204) | | |
| 14. Original Due Date: <u>May 1, 2000</u> <input type="checkbox"/> None | | |
| 15. Petition is hereby made to extend the <u>original</u> due date to cover the date this CPA is filed for which the requisite fee is attached | (1mo)- \$110/\$55= \$ _____ (2mos)- \$380/\$190= \$ _____ (3mos)- \$870/\$435= \$ _____ | (115/215) (116/216) (117/217) |
| 16. Enter any previous extension fee <u>paid</u> since above <u>original</u> due date (item 14) and subtract | - \$ 0 | |
| 17. EXTENSION FEE ATTACHED | \$ 870 | |
| 18. TOTAL FILING FEE = | \$ 1560 | |
| 19. If "petition" box 7 above is X'd, ----- add petition fee (\$130) | + 0 (122) | |
| 20. FEE ATTACHED = | \$ 1560 (carry forward to line 27) | |

(FOR AMENDMENT FEES RE ITEM 2 ABOVE SEE NEXT PAGE)

**22. ADDITIONAL FEE CALCULATION FOR PRELIMINARY AMENDMENT
TO BE ENTERED (PER ITEM 2 ABOVE)**

29.*If the entry in the first space is less than entry in the middle space, the "Present Extra" result is "0".

30.**If the "Highest number previously paid for" (see item 11 above) is less than 20, write "20" in this space.


31.***If the "Highest number previously paid for" (see item 12 above) is less than 3, write "3" in this space.

| | |
|---------------------------------|--------|
| Our Deposit Account No. 03-3975 | |
| Our Order No. | 11468 |
| | 235299 |
| C# | M# |

32. CHARGE STATEMENT: The Commissioner is hereby authorized to charge any fee specifically authorized hereafter, or any missing or insufficient fee(s) filed, or asserted to be filed, or which should have been filed herewith or concerning any paper filed hereafter, and which may be required under Rules 16-18 (missing or insufficient fee only) now or hereafter relative to this application and the resulting Official document under Rule 20, or credit any overpayment, to our Account/Order Nos. shown above for which purpose a duplicate copy of this sheet is attached. **This CHARGE STATEMENT does not authorize charge of the issue fee until/unless an issue fee transmittal form is filed.**

Pillsbury Madison & Sutro LLP
Intellectual Property Group

1100 New York Avenue, NW
Ninth Floor
Washington, DC 20005-3918
Tel: (202) 861-3000
Atty./Sec. ASH/maf

By Atty: Ann S. Hobbs Reg. No. 36830
Sig:  Fax: (202) 822-0944
Tel: (202) 861-3063

NOTE: No. 1: File this Request in duplicate with PTO receipt (PAT-103A) & attachments.
NOTE: No. 2: Is extension necessary for copendency? **DOUBLE CHECK** Item 14 above.


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re PATENT APPLICATION of

BOUCHARD, et al.

Appln. No.: 08/786,937

Filed: January 22, 1997



Group Art Unit: 1654

Examiner: Delacroix-Muirhead

#21/L
JRP
8/8/00

FOR: LHRH-ANTAGONISTS IN THE
TREATMENT OF FERTILITY DISORDERS

* * * * *

July 31, 2000

PRELIMINARY AMENDMENT

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

RECEIVED

AUG 03 2000

TECH CENTER 1600/2900

Sir:

Please enter the following amendments and consider the following remarks.

IN THE CLAIMS:

Enter the following claims:

--34. The method of claim 15 wherein the single or dual dose regimen is administered in an amount of 3 mg.

35. The method of claim 15 wherein the multiple dose regimen is administered in an amount of 0.25 mg/day.

36. The method of claim 21 wherein the single or dual dose regimen is administered in an amount of 3 mg.

37. The method of claim 21 wherein the multiple dose regimen is administered in an amount of 0.25 mg/day.--